AU Patent

AU2013245503B2 — Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors

Assigned to Pharmacyclics LLC · Expires 2015-09-24 · 11y expired

What this patent protects

Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid …

USPTO Abstract

Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013245503B2
Jurisdiction
AU
Classification
—
Expires
2015-09-24
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.